Optimize Regeneration Using
the Purest and Most Potent
Tissue Allograft and Amniosomes™
For homologous use only.
Screened for SARS-CoV-2
GO FAR BEYOND SINGLE MATERIAL ALLOGRAFT TO FOUR MATERIALS: RICHGEN® flowable allograft
“Single birth” donor derived placenta, amnion membrane, Wharton’s jelly, and amniotic fluid meet regulations as are not combined multiple donor material.
GO BEYOND: INTRODUCING PURE POTENT AMNIOSOMES™ - NEW!
Sourced from "Single birth" placental donors, potent amnio-derived extracellular vesicles are suspended in clarified amniotic fluid. Cryofrozen to preserve the full spectrum functional miRNA, RNA, peptides, and growth factors that support fetal development. Particulate debris are carefully filtered out for the most PURE extracellular vesicle product available today: Amniosomes™.
GO FAR BEYOND OUTDATED INVASIVE ADIPOSE AND BONE MARROW ASPIRATE TO OFF THE SHELF BIOLOGICS
Welcome to RichSource
RICHGEN Tissue Allograft and Amniosomes™
The most bioactive human tissue allograft and extracellular vesicles regenerative products on the market - are here.
Yes, after years of research and development all four materials are off the shelf ready to use one vial. The proprietary processing advances and new self-developed equipment have now also created the most pure and potent exosomes product. Both are made at a registered and certified laboratory in FL, USA. The biologics are regulated as human cellular or tissue-based product (HCT/P) under 21 CFR Part 1271.10 and Section 361 of the Public Health Service Act, FDA and ISO 13485 guidelines. FDA, AATB, cGMP and cGTP compliant. See FDA Publication of 21 CFR 1271 legal interpretation of PHSA section 351 v 361 that 361 manufacturing is allowed. An FDA IND has already been submitted for Amniosomes™ and an IND will be submitted 2020 for our new upcoming flowable allograft being released August 2020.
The RICHGEN flowable allografts’ bioactive proteins, combined with the presence of the extracellular matrix, laminin, and fibronectin, present a functional allograft that is effective in a wide array of applications. The Amniosomes™ present a product comprised of the best signaling messenger EVs and cleaned of debris particulates with new self-developed technology. The applications range from topical wound healing to rapid response for use in orthopedic pathologies, organ system pathologies, pain / anti-inflammatory control, scar management by following the inflammatory chemotactic pathways and providing components, immunomodulation, and scaffolding for healthy tissue generation and repair of injured tissue. For homologous use only. Expect only the best of products represented by RichSource.
Physicians nationwide have advanced
their practices with RICHGEN off the shelf products.
Using RICHGEN products provide your patients with non-invasive, non-surgical options. Even better, they will save you time, reduce your liability and bring in a new revenue stream. Additionally, Login and see our 100% guaranteed payment plan for patient treatments using RichSource distributed RICHGEN products.
Available in 0.5 ml, 1 ml, and 2 ml vials
- • Single donor FOUR materials
- • Full flexible signaling messaging
- • All 1,500 growth factor proteins
- • CD73, CD90, CD105, CD106, Stro-1
- • Exosomes, cytokines, secretomes, miRNA
- • Reduce time, eliminating surgery
- • Cells are never centrifuged
- • New manufacturer is an independent
processing lab with certifications.
Manufactured per 21 CFR 1271.10(a), PHS 361
and per AATB, GMP, cGMP, and cGTP
- • Collagen substrates II, IV, V and VII
- • Undifferentiated pluripotent and multipotent
- • Fibroblasts, Keratinocytes
- • Epithelial & Endothelial cells
- • Screened for SARS-CoV-2
- • Reduce liability, eliminating surgery
- • Provide patients non-invasive choice
- • Only freeze outer membrane of cells
- • For homologous use only
- • Does not contain umbilical cord blood
- • FDA Exemption 1271.3 (2) (bb)
Pure and Potent Amnio Exosomes
Available in 1 ml vials
- • Amniosomes™ are sourced from
pre-screened single donors in
compliance with HCT/Ps for donor
suitability per 21 CFR 1271.10
including screening for SARS-CoV-2.
- • Amniosomes™ is an a cellular human
allograft of amnio derived extracellular
vesicles that are preserved in their
natural state suspended in clarified
- • EVs are signaling messengers of MiRNA,
RNA, peptides, growth factors and more.
- • Using proprietary processing, the most
POTENT beneficial EVs are targeted and
- • Particulate debris are carefully filtered
out for the most PURE EV product.
- • Screened per FDA regulations including
- • Cryopreservation to preserve proteins.
- • For homologous use only.
- • Manufacturer is an FDA registered facility in
compliance with 21CFR1271.10(a), PHS 361
and per AATB, GMP, cGMP, and cGTP
- • FDA IND application submission April 14,
Additional RICHGEN Products:
RICHGEN unparalleled products are
undifferentiated pluripotent cellular
components with all supporting growth
factors, bioactive cytokines and other
The RICHGEN flowable allograft injectables are immunomodulating and they have the ability to secrete via exosomes and vesicles the appropriate combination of growth factors and miRNA to influence the surrounding tissue to regenerate.
The extracellular and intracellular messaging from the RICHGEN growth factors BMP 4, 5 and 7 enhance bone growth, the alpha2 macroglobulin enhances anti-inflammatory activity in the joints, the collagen substrates I, III, IV, V and VI, fibronectin and laminin enhance wound healing. The allograft has an immuno-modulating effect on the macrophages and CD45 expresses T cell activation. The placental allograft components drive the development of fully functional cellular repair and regeneration. Bone marrow development,the cells tend to lend themselves to marginally functional cellular development and the cells express inflexible signaling instructions. The RICHGEN cellular components have an immuno-modulatory effect and a trophic effect. In addition, RICHGEN products are never centrifuged and not combined with millions of lecithin that can artificially increase cell counts. RICHGEN is a pure product carefully prepared for maximum effect and safety.
Umbilical cord blood cells are multi-potent, do not differentiate and are made with multiple donor blood often leaving RBCs in the product and have caused host adverse reactions and infections. To create optimization inject using RICHGEN, single donor material flowable allograft. What's more, RICHGEN's important proprietary processing does not crystallize the inner cells in the freezing process, just the outer membrane. The result is our thawed product is the most leading edge today. Doctors have ease of use and time savings. Please visit the Physician Portal.